Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Melbourne, Australia
- Research Site
Denver, Colorado, United States
- Research Site
Sarasota, Florida, United States
- Research Site
Detroit, Michigan, United States
- Research Site
Charlotte, North Carolina, United States
- Research Site
Canton, Ohio, United States
- Research Site
Oklahoma City, Oklahoma, United States
- Research Site
Nashville, Tennessee, United States
- Research Site
Dallas, Texas, United States
- Research Site
Houston, Texas, United States
- Research Site
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2017
- Primary completion
- 25 Mar 2021
- Completion
- 25 Mar 2021
- Last update posted
- 5 Apr 2022
- Registered enrollment
- 50
- Registry id
- NCT03217838
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.